Increase of therapeutic activity of doxorubicin by long circulating liposomes in combination with curcumin

Pharmazie

Volumn 66, Issue 11, 2011, Pages 871-874

  Wang, Hong ^a   Hu, LianDong ^b   Li, Chunlei ^c   Zhang, Jingguo ^b   Zhang, Tao ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI UNIVERSITY   (China)

^c CSPC ZhongQi Pharmaceutical Technology Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMA LONGA EXTRACT; CURCUMIN; DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CURCUMA LONGA; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SYNTHESIS; ENTRAPMENT EFFICIENCY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RABBIT; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD VESSELS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DOXORUBICIN; DRUG COMPOUNDING; EAR, EXTERNAL; HEMOLYSIS; IRRITANTS; LIPOSOMES; RABBITS; SKIN;

EID: 84055200241     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.1057     Document Type: Article

References (12)

1. Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41: 40-59.
2. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23: 363-398. (Pubitemid 36361976)
3. Dresdale A, Bonow RO, Wesley R, Palmeri ST, Barr L, Mathison D, D'Angelo T, Rosenberg SA (1983) Prospective evaluation of doxorubicininduced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas. Cancer 52: 51-60. (Pubitemid 13057607)
4. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42: 419-436. (Pubitemid 36649037)
5. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug resistance efflux pump. Clin Cancer Res 6: 1949-1957. (Pubitemid 30305094)
6. Moreira JN, Hansen CB, Gaspar R, AllenTM(2001)Agrowth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim Biophys Acta 1514: 303-317. (Pubitemid 32831017)
7. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC (2001) Tumor targeting using anti-her2 immunoliposomes, J Control Release 74: 95-113. (Pubitemid 32727613)
8. Ruby, AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R (1995) Antitumour and antioxidant activity of natural curcuminoids. Cancer Lett 94:79-83.
9. Speth PA, van Hoesel QG, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15: 15-31.
10. Sridhar R, Dwivedi C, Anderson J, Baker PB, Sharma HM, Desai P, Engineer FN (1992) Effects of verapamil on the acute toxicity of doxorubicin in vivo. J National Cancer Inst 21: 1653-1660.
11. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc 12: 1672-1677.
12. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers;1;(2005) Nature Rev Drug Discov 2: 145-160.